(Estradiol + progesterone) is under clinical development by Dare Bioscience and currently in Phase II for Genitourinary Syndrome of Menopause (GSM). According to GlobalData, Phase II drugs for Genitourinary Syndrome of Menopause (GSM) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Estradiol + progesterone) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Estradiol + progesterone) overview
Estradiol in combination with progesterone is under development as hormone replacement therapy (HRT) for vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause. It is administered through vaginal route as a ring. Estrogen acts by targeting on estrogen receptors and progesterone acts by targeting progesterone receptor. It is developed based on segmented intra-vaginal ring (IVR) technology.
Dare Bioscience overview
Dare Bioscience, formerly Cerulean Pharma, is a biopharmaceutical company that develops products for women’s reproductive health. The company, through its dynamic tumor targeting platform, creates nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. It offers products that include ovaprene, a clinical stage, non-hormonal contraceptive ring that provides protection over multiple weeks of use; and topical 5% sildenafil citrate cream for women with female sexual arousal disorders. The company develops and markets therapies for women in the areas of contraception, vaginal health, sexual health and fertility. It offers services across the US. Dare Bioscience is headquartered in San Diego, California, the US.
For a complete picture of (Estradiol + progesterone)’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
